Induced pluripotent stem cells as a cell-based therapeutic in stroke

David C Hess, Nasir Fakhri, Franklin D. West

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Induced pluripotent stem cells (iPSC) represent a major breakthrough in stem cell research, cell therapy, and regenerative medicine. iPSC have immediate applications in modeling diseases, such as amyotrophic lateral sclerosis, and testing drugs on differentiated human cells in vitro. There is also a growing body of evidence that demonstrates efficacy of iPSC-derived neural progenitor cells in preclinical stroke models in the rodent. Unlike other types of cells such as mesenchymal stem cells that work by immunomodulatory and trophic effects, iPSC work by both “cell replacement” and trophic effects on surrounding tissue. The future clinical use of iPSC-based therapy in regenerative medicine and specifically stroke is still years away and will require overcoming some remaining hurdles. These include the need for safe, nongenomic integrative reprogramming methods to remove the risk of tumor development, choosing the optimal iPSC-derived neural progenitors to transplant, determining the ideal routes, timing, and doses of cell transplantation, and developing good manufacturing practices (GMP) to safely expand and maintain the cells for clinical use. While both autologous and allogeneic transplantations are options, feasibility, cost, and scalability will make allogeneic transplantation the more likely approach.

Original languageEnglish (US)
Title of host publicationCell Therapy for Brain Injury
PublisherSpringer International Publishing
Pages129-146
Number of pages18
ISBN (Electronic)9783319150635
ISBN (Print)9783319150628
DOIs
StatePublished - Jan 1 2015

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
Stroke
Regenerative Medicine
Homologous Transplantation
Cell- and Tissue-Based Therapy
Therapeutics
Stem Cell Research
Autologous Transplantation
Cell Transplantation
Amyotrophic Lateral Sclerosis
Mesenchymal Stromal Cells
Transplants
Rodentia
Stem Cells
Scalability
Costs and Cost Analysis
Tumors
Cells
Tissue

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Neuroscience(all)

Cite this

Hess, D. C., Fakhri, N., & West, F. D. (2015). Induced pluripotent stem cells as a cell-based therapeutic in stroke. In Cell Therapy for Brain Injury (pp. 129-146). Springer International Publishing. https://doi.org/10.1007/978-3-319-15063-5_9

Induced pluripotent stem cells as a cell-based therapeutic in stroke. / Hess, David C; Fakhri, Nasir; West, Franklin D.

Cell Therapy for Brain Injury. Springer International Publishing, 2015. p. 129-146.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hess, DC, Fakhri, N & West, FD 2015, Induced pluripotent stem cells as a cell-based therapeutic in stroke. in Cell Therapy for Brain Injury. Springer International Publishing, pp. 129-146. https://doi.org/10.1007/978-3-319-15063-5_9
Hess DC, Fakhri N, West FD. Induced pluripotent stem cells as a cell-based therapeutic in stroke. In Cell Therapy for Brain Injury. Springer International Publishing. 2015. p. 129-146 https://doi.org/10.1007/978-3-319-15063-5_9
Hess, David C ; Fakhri, Nasir ; West, Franklin D. / Induced pluripotent stem cells as a cell-based therapeutic in stroke. Cell Therapy for Brain Injury. Springer International Publishing, 2015. pp. 129-146
@inbook{1469cb4e15124395b05e58c8e86eed4c,
title = "Induced pluripotent stem cells as a cell-based therapeutic in stroke",
abstract = "Induced pluripotent stem cells (iPSC) represent a major breakthrough in stem cell research, cell therapy, and regenerative medicine. iPSC have immediate applications in modeling diseases, such as amyotrophic lateral sclerosis, and testing drugs on differentiated human cells in vitro. There is also a growing body of evidence that demonstrates efficacy of iPSC-derived neural progenitor cells in preclinical stroke models in the rodent. Unlike other types of cells such as mesenchymal stem cells that work by immunomodulatory and trophic effects, iPSC work by both “cell replacement” and trophic effects on surrounding tissue. The future clinical use of iPSC-based therapy in regenerative medicine and specifically stroke is still years away and will require overcoming some remaining hurdles. These include the need for safe, nongenomic integrative reprogramming methods to remove the risk of tumor development, choosing the optimal iPSC-derived neural progenitors to transplant, determining the ideal routes, timing, and doses of cell transplantation, and developing good manufacturing practices (GMP) to safely expand and maintain the cells for clinical use. While both autologous and allogeneic transplantations are options, feasibility, cost, and scalability will make allogeneic transplantation the more likely approach.",
author = "Hess, {David C} and Nasir Fakhri and West, {Franklin D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-15063-5_9",
language = "English (US)",
isbn = "9783319150628",
pages = "129--146",
booktitle = "Cell Therapy for Brain Injury",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Induced pluripotent stem cells as a cell-based therapeutic in stroke

AU - Hess, David C

AU - Fakhri, Nasir

AU - West, Franklin D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Induced pluripotent stem cells (iPSC) represent a major breakthrough in stem cell research, cell therapy, and regenerative medicine. iPSC have immediate applications in modeling diseases, such as amyotrophic lateral sclerosis, and testing drugs on differentiated human cells in vitro. There is also a growing body of evidence that demonstrates efficacy of iPSC-derived neural progenitor cells in preclinical stroke models in the rodent. Unlike other types of cells such as mesenchymal stem cells that work by immunomodulatory and trophic effects, iPSC work by both “cell replacement” and trophic effects on surrounding tissue. The future clinical use of iPSC-based therapy in regenerative medicine and specifically stroke is still years away and will require overcoming some remaining hurdles. These include the need for safe, nongenomic integrative reprogramming methods to remove the risk of tumor development, choosing the optimal iPSC-derived neural progenitors to transplant, determining the ideal routes, timing, and doses of cell transplantation, and developing good manufacturing practices (GMP) to safely expand and maintain the cells for clinical use. While both autologous and allogeneic transplantations are options, feasibility, cost, and scalability will make allogeneic transplantation the more likely approach.

AB - Induced pluripotent stem cells (iPSC) represent a major breakthrough in stem cell research, cell therapy, and regenerative medicine. iPSC have immediate applications in modeling diseases, such as amyotrophic lateral sclerosis, and testing drugs on differentiated human cells in vitro. There is also a growing body of evidence that demonstrates efficacy of iPSC-derived neural progenitor cells in preclinical stroke models in the rodent. Unlike other types of cells such as mesenchymal stem cells that work by immunomodulatory and trophic effects, iPSC work by both “cell replacement” and trophic effects on surrounding tissue. The future clinical use of iPSC-based therapy in regenerative medicine and specifically stroke is still years away and will require overcoming some remaining hurdles. These include the need for safe, nongenomic integrative reprogramming methods to remove the risk of tumor development, choosing the optimal iPSC-derived neural progenitors to transplant, determining the ideal routes, timing, and doses of cell transplantation, and developing good manufacturing practices (GMP) to safely expand and maintain the cells for clinical use. While both autologous and allogeneic transplantations are options, feasibility, cost, and scalability will make allogeneic transplantation the more likely approach.

UR - http://www.scopus.com/inward/record.url?scp=84943385371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943385371&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15063-5_9

DO - 10.1007/978-3-319-15063-5_9

M3 - Chapter

AN - SCOPUS:84943385371

SN - 9783319150628

SP - 129

EP - 146

BT - Cell Therapy for Brain Injury

PB - Springer International Publishing

ER -